Blog
RSS FeedPosted by Michael Wonder on 24 Feb 2021
Health Canada approves Dupixent (dupilumab) as the first biologic for the treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years
23 February 2021 - Dupixent is the only biologic medicine approved to treat atopic dermatitis for this patient population. ...
Posted by Michael Wonder on 23 Dec 2020
Health Canada approves ALK's Ragwitek sublingual allergy immunotherapy tablets for paediatric patients with ragweed allergy
22 December 2020 - With the indication expanded to paediatric patients, ALK Canada now provides adults and children a SLIT tablet ...
Posted by Michael Wonder on 30 Jul 2020
Health Canada Approves Brivlera (brivaracetam) to treat partial-onset seizures in paediatric epilepsy patients
29 July 2020 - Health Canada's approval of Brivlera provides paediatric epilepsy patients with a treatment option which can be initiated ...
Posted by Michael Wonder on 10 Mar 2020
Health Canada approves fast-acting mealtime insulin, Fiasp, for children with diabetes
9 March 2020 - Health Canada also expands Fiasp approval to include insulin infusion pumps. ...
Posted by Michael Wonder on 30 Sep 2019
Health Canada approves Dupixent as the first biologic for the treatment of adolescents with moderate-to-severe atopic dermatitis
27 September 2019 - Dupixent can significantly reduce the constant itch and improve the skin's overall condition. ...
Posted by Michael Wonder on 26 Jul 2019
Federal health minister announces new treatment options for children
25 July 2019 - Health Minister Ginette Petitpas Taylor made the announcement at Health Sciences North in Sudbury on Thursday. ...
Posted by Michael Wonder on 11 Jul 2019
Health Canada has authorised Vyvanse (lisdexamphetamine dimesylate), the first and only, chewable tablet for the treatment of attention deficit/hyperactivity disorder
10 July 2019 - Vyvanse offers an additional option for patients who prefer the convenience of a chewable tablet, or who ...
Posted by Michael Wonder on 21 Feb 2019
AbbVie's Humira (adalimumab) approved by Health Canada to treat paediatric patients with chronic non-infectious anterior uveitis
20 February 2019 - The approval marks Humira as the only approved biologic treatment option in Canada for paediatric patients from ...
Posted by Michael Wonder on 14 Dec 2018
Health Canada grants market authorisation for Orkambi (lumacaftor/ivacaftor) for children with cystic fibrosis aged 2 to 5 years old with most common form of the disease
13 December 2018 - Orkambi is the first medicine in Canada to treat the underlying cause of cystic fibrosis in young ...
Posted by Michael Wonder on 06 Dec 2018
Alberta boy with thyroid cancer runs, plays after taking U.S. approved drug
5 December 2018 - Health Canada is considering approving the oral treatment, larotrectinib. ...
Posted by Michael Wonder on 02 Oct 2018
Health Canada approves Tresiba for children with Type 1 diabetes
1 October 2018 - Rates of Type 1 diabetes among children and youth on the rise globally. ...
Posted by Michael Wonder on 19 Sep 2018
Sunovion announces Health Canada approval of Aptiom (eslicarbazepine acetate) as adjunctive therapy for the treatment of partial-onset seizures in adolescents and children above six years of age
19 September 2018 - Sunovion Pharmaceuticals today announced that Health Canada approved the supplemental new drug submission to expand the ...
Posted by Michael Wonder on 02 Nov 2017
Pediapharm receives Health Canada approval for Cuvposa
1 November 2017 - Pediapharm is very pleased to announce Health Canada's notice of compliance (approval) for Cuvposa (Glycopyrrolate oral ...
Posted by Michael Wonder on 06 Jun 2017
Workshop: addressing unmet needs of children with pulmonary arterial hypertension
6 June 2017 - The EMA, the United States FDA and Health Canada are co-organising a workshop to discuss the ...